BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu BS, Tang T, Jia JL, Xie BC, Wu TL, Sheng YY, Xue YZ, Tang HM. CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling. Cancer Cell Int 2020;20:513. [PMID: 33093811 DOI: 10.1186/s12935-020-01605-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hashimoto K. CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. Cancers (Basel) 2021;13:2288. [PMID: 34064598 DOI: 10.3390/cancers13102288] [Reference Citation Analysis]
3 Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers (Basel) 2021;13:4363. [PMID: 34503172 DOI: 10.3390/cancers13174363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ding J, Jiang N, Zheng Y, Wang J, Fang L, Li H, Yang J, Hu A, Xiao P, Zhang Q, Chai D, Zheng J, Wang G. Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity. Pharmacol Res 2021;175:106034. [PMID: 34915126 DOI: 10.1016/j.phrs.2021.106034] [Reference Citation Analysis]